Strong M&A momentum in 2026, with global deal value up over 40% year-over-year through midyear and megadeals exceeding $10 billion surging, continues to shape trader views on acquisition timelines before 2027. Biotech and AI infrastructure have led activity, evidenced by Eli Lilly’s multiple oncology and vaccine deals plus record funding rounds for OpenAI and Anthropic, while sectors like healthcare and technology see portfolio reshaping amid flat valuations around 11.6x EV/EBITDA. Pending closings, regulatory reviews, and potential private equity revival in infrastructure hinge on credit conditions and antitrust scrutiny, with trader consensus reflecting these catalysts alongside broader economic data releases.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$18,251,900 Vol.

MGM Resorts
27%

Viking Therapeutics
16%

PayPal
14%

Snapchat
12%

Brown-Forman
12%

Perplexity AI
12%

GitLab
8%

Zoom Video Communications
7%

Lovable
6%

Anthropic
3%

BP
3%

Nebius Group
3%

Ubisoft
2%

OpenAI
2%
$18,251,900 Vol.

MGM Resorts
27%

Viking Therapeutics
16%

PayPal
14%

Snapchat
12%

Brown-Forman
12%

Perplexity AI
12%

GitLab
8%

Zoom Video Communications
7%

Lovable
6%

Anthropic
3%

BP
3%

Nebius Group
3%

Ubisoft
2%

OpenAI
2%
Mergers where the listed company is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between the listed company and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from the listed company and/or its leadership; however, a consensus of credible reporting will also be used.
Market Opened: Nov 24, 2025, 12:48 PM ET
Resolver
0x65070BE91...Mergers where the listed company is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between the listed company and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from the listed company and/or its leadership; however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Strong M&A momentum in 2026, with global deal value up over 40% year-over-year through midyear and megadeals exceeding $10 billion surging, continues to shape trader views on acquisition timelines before 2027. Biotech and AI infrastructure have led activity, evidenced by Eli Lilly’s multiple oncology and vaccine deals plus record funding rounds for OpenAI and Anthropic, while sectors like healthcare and technology see portfolio reshaping amid flat valuations around 11.6x EV/EBITDA. Pending closings, regulatory reviews, and potential private equity revival in infrastructure hinge on credit conditions and antitrust scrutiny, with trader consensus reflecting these catalysts alongside broader economic data releases.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions